Connect with us
European Gaming Congress 2024

Artificial Intelligence

Global Red Biotechnology Market Report 2023: Sector is Expected to Reach $997.74 Billion by 2030 at a CAGR of 10.6%

Published

on

Dublin, June 09, 2023 (GLOBE NEWSWIRE) — The “Red Biotechnology Market Size, Share & Trends Analysis Report By Product, By End-user (Academic Research Institutes, CMOs & CROs, Pharmaceutical & Biotechnology Companies, Others), By Region, And Segment Forecasts, 2023 – 2030” report has been added to ResearchAndMarkets.com’s offering.

The global red biotechnology market size is expected to reach USD 997.74 billion by 2030 expanding at a CAGR of 10.6% from 2023 to 2030.

Companies Mentioned

  • Merck KGaA
  • Hoffmann-La Roche, Ltd.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • AstraZeneca Plc.
  • Takeda Pharmaceutical Company Limited
  • Gilead Sciences
  • Biogen Inc.
  • Amgen Inc.
  • Celgene Corporation

Red biotechnology has emerged as a most dynamic fields in terms of innovation in past few years. With increasing burden of chronic illnesses such as cancers, genetic disorders, diabetes, and many more, the demand for vaccines, monoclonal antibodies, gene therapies, and cell therapies has grown significantly.

Robust pipeline is also expected to propel the growth of red biotechnology market on account of number of expected regulatory approvals in coming years.

COVID- 19 pandemic also had a positive impact on the global market. The approval of various vaccines for management of the virus injected huge revenues within the market place. Similarly enormous number of research studies done for mapping the virus and formulating the vaccine resulted in an increased demand for antibodies, recombinant proteins, enzymes, and many more.

Advertisement

For instance, in May 2022, Bharat Biotech received a funding of USD 19 million from Coalition for Epidemic Preparedness Innovations to develop variant proof vaccine against the COVID-19 virus. The pandemic also marked entry of huge number of startups pertaining to biotechnology space creating new market opportunities in emerging countries.

The biotechnology industry is being impacted by Artificial Intelligence (AI), which is important for many processes involved in creating alternative treatments. In the process of developing new medications, artificial intelligence and machine learning are routinely used now. Machine learning makes it easier to find small compounds with medicinal potential based on known target architectures. Increasing adoption of AI in clinical and preclinical studies is expected to reduce the time required to carry out these studies, which in turn is expected to increase the demand for red biotechnology subsets in coming years.

Red Biotechnology Market Report Highlights

  • By product, the monoclonal antibody is considered to be a relatively more mature and dominant segment compared to other products in the red biotechnology market. Increasing sales and improved efficacy of these drugs are the major reason for the segment dominant. Large number of drug approvals in past years has resulted in huge revenue generation.
  • By end-user, the pharmaceutical & biotechnology companies accounted for majority of revenue in the red biotechnology industry. Increasing number of clinical trials being performed by the companies, growth in R&D and robust pipeline is expected to be the major factors effecting the revenue growth of the segment
  • North America has emerged a strong regional position in the market with 38.07% share of the overall market in 2022. The increasing incidence rate of cancer and high R&D expenditure are encouraging companies to undertake product development in the region.

Key Topics Covered:

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Advertisement

Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.4.1. Increasing R&D funding in the biotechnology industry.
3.4.2. Rising prevalence of chronic diseases.
3.4.3. Technological advancements across multiple platforms
3.4.4. Declining prices of DNA sequencing
3.5. Market Restraint Analysis
3.5.1. High level of investment in developing technologically advanced products
3.5.2. Ethical & legal limitations
3.6. Penetration and Growth Prospect Mapping 2022
3.7. Business Environment Analysis
3.7.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.7.2. Porter’s Five Forces Analysis
3.8. COVID-19 Impact Analysis

Chapter 4. Product Business Analysis
4.1. Red Biotechnology Market: Product Movement Analysis
4.2. Monoclonal Antibodies
4.2.1. Monoclonal Antibodies Market, 2018 – 2030 (USD Billion)
4.3. Polyclonal Antibodies
4.3.1. Polyclonal Antibodies Market, 2018 – 2030 (USD Billion)
4.4. Recombinant Proteins
4.4.1. Recombinant Proteins Market, 2018 – 2030 (USD Billion)
4.5. Vaccines
4.5.1. Vaccines Market, 2018 – 2030 (USD Billion)
4.6. Cell-Based Immunotherapy Products
4.6.1. Cell-Based Immunotherapy Products Market, 2018 – 2030 (USD Billion)
4.7. Gene Therapy Products
4.7.1. Gene Therapy Products Market, 2018 – 2030 (USD Billion)
4.8. Cell Therapy Products
4.8.1. Cell Therapy Products Market, 2018 – 2030 (USD Billion)
4.9. Tissue-Engineered Products
4.9.1. Tissue-Engineered Products Market, 2018 – 2030 (USD Billion)
4.10. Stem Cells
4.10.1. Stem Cells Market, 2018 – 2030 (USD Billion)
4.11. Cell Culture
4.11.1. Cell Culture Market, 2018 – 2030 (USD Billion)
4.12. Viral Vector
4.12.1. Viral Vector Market, 2018 – 2030 (USD Billion)
4.13. Enzymes
4.13.1. Enzymes Market, 2018 – 2030 (USD Billion)
4.14. Kits and Reagents
4.14.1. Kits and Reagents Market, 2018 – 2030 (USD Billion)
4.15. Animal Models
4.15.1. Animal Models Market, 2018 – 2030 (USD Billion)
4.16. Molecular Diagnostics
4.16.1. Molecular Diagnostics Market, 2018 – 2030 (USD Billion)
4.17. Others
4.17.1. Others Market, 2018 – 2030 (USD Billion)

Chapter 5. End-User Business Analysis
5.1. Red Biotechnology Market: End-User Movement Analysis
5.2. Academic Research Institutes
5.2.1. Academic Research Institutes Market, 2018 – 2030 (USD Billion)
5.3. CMOs & CROs
5.3.1. CMOs & CROs Market, 2018 – 2030 (USD Billion)
5.4. Pharmaceutical & Biotechnology Companies
5.4.1. Pharmaceutical & Biotechnology Companies Market, 2018 – 2030 (USD Billion)
5.5. Others
5.5.1. Others Market, 2018 – 2030 (USD Billion)

Chapter 6. Regional Business Analysis

Chapter 7. Competitive Landscape
7.1. Company Categorization
7.2. Company Market Share Analysis, 2022
7.3. Strategy Mapping
7.4. Company Profiles/Listing

Advertisement

For more information about this report visit https://www.researchandmarkets.com/r/evyap7

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Xinhua Silk Road: E China’s Changzhou City unveils investment opportunities in sectors of new productive forces for global investors

Published

on

xinhua-silk-road:-e-china’s-changzhou-city-unveils-investment-opportunities-in-sectors-of-new-productive-forces-for-global-investors

BEIJING, Sept. 29, 2024 /PRNewswire/ — Changzhou City, an leading international smart manufacturing base located in east China’s Jiangsu Province, has released a bunch of investment investment opportunities to global investors in various sectors of new productive forces at the the 2024 New Energy Industry Development Conference & Invest in Changzhou Conference held in the city on September 19.

The investment opportunities covers nine areas including synthetic biology, low-altitude economy, intelligent connected new energy vehicles, solid-state batteries, hydrogen energy, third-generation semiconductors, and artificial intelligence, manifesting the confidence of Changzhou in further opening development. 
Changzhou, seated in the axis of the Yangtze River Delta, has become an important base for advanced manufacturing in China.
In recent years, thanks to intensified efforts in developing new energy industry and fostering new quality productive forces, Changzhou has expanded the added value of its industrial sector to more than two trillion yuan, with manufacturing added value accounting for about 43 percent, both ranking among the top three in Jiangsu Province.
In the Hurun China New Energy Cities 2024, a list released by the Hurun Research Institute at the conference, Changzhou ranked first among other cities in the country for three consecutive years in terms of investment attractiveness and concentration.
Changzhou has accumulated a total of 10.59 billion US dollars (nearly 74.25 billion yuan) in terms of actually utilized foreign capital since 2020. Major projects such as soft magnetism of ArcelorMittal and medical device of BIOS, a Hong Kong-based company, have been launched during the conference. 
In addition, Changzhou has released a multilingual guide for foreign nationals in Changzhou at the conference, which includes practical service items in stay and residence, work, convenient payment options, among others, turning the city into a more open and international place.
Original link: https://en.imsilkroad.com/p/342380.html
Photo – https://mma.prnewswire.com/media/2518604/Changzhou.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/xinhua-silk-road-e-chinas-changzhou-city-unveils-investment-opportunities-in-sectors-of-new-productive-forces-for-global-investors-302261868.html

Continue Reading

Artificial Intelligence

CGTN: China honors individuals with highest awards in celebration of 75th National Day

Published

on

cgtn:-china-honors-individuals-with-highest-awards-in-celebration-of-75th-national-day

BEIJING, Sept. 29, 2024 /PRNewswire/ — Huang Zongde enlisted in the Chinese People’s Liberation Army at the age of 17, beginning a nearly four-decade-long military career where his bravery, valor and devotion earned him countless awards and honors.

The heavily decorated 93-year-old received the highest state honor on Sunday when Chinese President Xi Jinping conferred him with the Medal of the Republic at a ceremony in the Great Hall of the People in Beijing.
China awarded national medals and national honorary titles to 15 individuals, including Huang, in recognition of their contribution and achievement as it celebrates the 75th anniversary of the founding of the People’s Republic of China, which falls on October 1.
Chinese heroes and role models
In addition to Huang, three others were awarded the Medal of the Republic. Wang Yongzhi, a missile and rocket expert and a pioneer of China’s manned space program, was honored posthumously. Wang Zhenyi, a medical scientist known for breakthroughs in leukemia treatment, and Li Zhensheng, an expert in wheat breeding, are also among the honorees.
The national honorary titles went to 10 people, including scientists, a border patrolman, an artist, a craftsman, educators, a health worker, an economist and an athlete.
Addressing Sunday’s awarding ceremony, President Xi, also general secretary of the Communist Party of China Central Committee and chairman of the Central Military Commission, called on the Chinese people to learn from heroes and role models to form a mighty force to build a strong China.
China is in a crucial period for building a great modern socialist country in all respects and achieving national rejuvenation through Chinese modernization, he said.
Encouraging the Chinese people to strive for extraordinary achievements at ordinary job posts, Xi urged them to contribute to resolving challenges to development and reform and safeguarding social harmony and stability.
China’s old friends and good friends
As its highest state honor for foreigners, China awarded the Friendship Medal to Dilma Rousseff, president of the New Development Bank and former Brazilian president, for her commitment to the friendship between China and Brazil, and development of relationship between China and the Community of Latin American and Caribbean States, and cooperation among BRICS countries, a group of major emerging economies.
Accepting the honor at the ceremony, Rousseff said the medal symbolizes the strong bonds between Brazil and China and pledged to continue her unremitting efforts to promote the friendship.
China’s achievements over the decades, including economic transformation, technological innovation and remarkable social development, have made it a beacon and a source of inspiration for the world, she said.
Xi lauded Rousseff as an outstanding representative of China’s old friends and good friends who have shared the same aspirations and stood together with the Chinese people over the past 75 years and vowed that China will never forget such international friends.
The Chinese people are ready to join hands with people from all over the world to safeguard world peace, promote common development and advance the building of a community with a shared future for mankind to create a better future for humanity, he said.
https://news.cgtn.com/news/2024-09-29/China-honors-individuals-with-highest-awards-ahead-of-National-Day-1xhS1SaZeZa/p.html
 

View original content:https://www.prnewswire.co.uk/news-releases/cgtn-china-honors-individuals-with-highest-awards-in-celebration-of-75th-national-day-302261867.html

Continue Reading

Artificial Intelligence

Kazakhstan Government Delegation Visited SUPCON

Published

on

kazakhstan-government-delegation-visited-supcon

HANGZHOU, China, Sept. 29, 2024 /PRNewswire/ — On September 26, a delegation from the Ministry of Digital Development, Innovations and Aerospace Industry of the Republic of Kazakhstan, led by Minister Madiyev Zhaslan, visited SUPCON. SUPCON’s Chairman and President, Mr.Cui Shan, warmly welcomed the delegation.

The Kazakhstan government representatives expressed their appreciation and recognition of SUPCON’s expertise and innovation in intelligent manufacturing, digital transformation, and industrial AI.
Madiyev Zhaslan expressed a strong interest in industrial AI technologies of SUPCON, particularly their applications in intelligent and low-carbon facilities. He looks forward to exploring extensive collaboration with SUPCON across various sectors in Kazakhstan.
Cui Shan emphasized that as a leading industrial AI company with a global presence, SUPCON will leverage its technological advantages to meet Kazakhstan’s industry development requirements and trends, injecting new momentum into the country’s industrial digitalization.
In 2023, SUPCON established a subsidiary in Kazakhstan as its Central Asia regional headquarters and set up a localized operational system. SUPCON will continue to invest in the long-term development of the Central Asia region, contributing further wisdom and strength to the industrial digital transformation in Kazakhstan and beyond.
Photo – https://mma.prnewswire.com/media/2518470/image_5022684_18905906.jpg Photo – https://mma.prnewswire.com/media/2518471/1.jpg

View original content:https://www.prnewswire.co.uk/news-releases/kazakhstan-government-delegation-visited-supcon-302261857.html

Continue Reading

Trending